Literature DB >> 34094659

Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview.

Min Liu1, Hongzhe Shi2, Jiaqing Yan1, Yuan Zhang1, Yinglin Ma1, Kaidi Le1, Zhongdong Li3, Nianzeng Xing2, Guohui Li1.   

Abstract

Numerous prostate cancer (PC) associated genes have been reported in previous genome-wide association studies. Elucidation of prostate cancer pharmacogenomics have enhanced studies into the impact of germline genetic changes on treatment, in addition to evaluating related genomic alterations and biomarkers in prostate tumor tissues. Currently, Abiraterone (Abi) is used as one of the therapeutic options for PC. In this article, germline variants that have been associated with responses to Abi in patients with advanced PC are summarized. These include biomarker genes such as CYP17A1, AR-V7, HSD3B1, SLCO2B1, SULT1E1, and SRD5A2 that are involved in homologous recombination, as well as in gene expression mutations in important signaling pathways, such as WNT and Abi metabolic pathways. AJCR
Copyright © 2021.

Entities:  

Keywords:  Genetic polymorphisms; abiraterone; androgen receptor; prognostic; prostate cancer

Year:  2021        PMID： 34094659      PMCID： PMC8167691     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN： 2156-6976            Impact factor:   6.166


  114 in total

Review 1.  Germline variants and response to systemic therapy in advanced prostate cancer.

Authors:  Eric Johnson; Roberto Nussenzveig; Neeraj Agarwal; Umang Swami
Journal:  Pharmacogenomics       Date:  2020-01       Impact factor: 2.533

2.  Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Mary Nakazawa; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  JAMA Oncol       Date:  2015-08       Impact factor: 31.777

3.  Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

Authors:  Elahe A Mostaghel; Brett T Marck; Stephen R Plymate; Robert L Vessella; Stephen Balk; Alvin M Matsumoto; Peter S Nelson; R Bruce Montgomery
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

4.  Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

Authors:  M Nakazawa; C Lu; Y Chen; C J Paller; M A Carducci; M A Eisenberger; J Luo; E S Antonarakis
Journal:  Ann Oncol       Date:  2015-06-27       Impact factor: 32.976

5.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

6.  Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.

Authors:  Johannes Hofland; Wytske M van Weerden; Natasja F J Dits; Jacobie Steenbergen; Geert J L H van Leenders; Guido Jenster; Fritz H Schröder; Frank H de Jong
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

7.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

8.  Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.

Authors:  Xiaotun Zhang; Colm Morrissey; Shihua Sun; Melanie Ketchandji; Peter S Nelson; Lawrence D True; Funda Vakar-Lopez; Robert L Vessella; Stephen R Plymate
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

9.  Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience.

Authors:  Pierangela Sepe; Elena Verzoni; Patrizia Miodini; Melanie Claps; Raffaele Ratta; Antonia Martinetti; Roberta Mennitto; Elisa Sottotetti; Giuseppe Procopio; Vera Cappelletti; Maria Grazia Daidone
Journal:  Cancers (Basel)       Date:  2019-07-13       Impact factor: 6.639

10.  Mesenchymal-transitioned cancer cells instigate the invasion of epithelial cancer cells through secretion of WNT3 and WNT5B.

Authors:  Shinichiro Kato; Yoshihiro Hayakawa; Hiroaki Sakurai; Ikuo Saiki; Satoru Yokoyama
Journal:  Cancer Sci       Date:  2014-01-29       Impact factor: 6.716
View more
  2 in total

Review 1.  Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer.

Authors:  Darren M C Poon; Kuen Chan; Tim Chan; Foo-Yiu Cheung; Daisy Lam; Martin Lam; Ka-Suet Law; Conrad Lee; Eric K C Lee; Angus Leung; Henry Sze; Chi-Chung Tong; Kenneth C W Wong; Philip Kwong
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

2.  Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis.

Authors:  Yo-Liang Lai; Chia-Hsin Liu; Shu-Chi Wang; Shu-Pin Huang; Yi-Chun Cho; Bo-Ying Bao; Chia-Cheng Su; Hsin-Chih Yeh; Cheng-Hsueh Lee; Pai-Chi Teng; Chih-Pin Chuu; Deng-Neng Chen; Chia-Yang Li; Wei-Chung Cheng
Journal:  Cancers (Basel)       Date:  2022-03-19       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.